If she can't be in the trial, she can still get access to the trial drug through 'expanded use'. www(DOT)fda(DOT)gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm#Expanded_Access_Requirements
We have all be waiting "patiently" for the 2-73 trial update that some expected as early as January. If the update is anything like the 5 week data, there might be no turning back with regard to the stock price. But we wait.
Now, we have received very impressive anecdotal evidence concerning the efficacy of 2-73 from the Australian trial in the form of video evidence coupled with the testimony of the loved ones of some trial participants, and not a peep from the company. The story/video is not even on their website.
Why would the company not want to take advantage of such positive press?